Bayer announced on Tuesday (August 8) a net loss of 1.89 billion euros ($2.08 billion) in the second quarter.
This was largely attributed to impairment charges amounting to 2.3 billion euros.
The official statement, backed by audited results, follows the initial July announcement by the German pharmaceutical and agrochemical company.
At that time, Bayer had indicated anticipated goodwill impairments of approximately 2.5 billion euros, resulting in a projected second-quarter net loss of 2 billion euros.
